Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System

Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System

Proteasome inhibitors (PIs) are an integral component of multiple myeloma therapies. Peripheral neuropathy (PN) is a well-known consequence of PIs, most frequently reported with earlier generations such as Bortezomib (BTZ). There is a paucity of data highlighting the risk of developing PN in the new...

Full description

Bibliographic Details
Main Authors: Syeda A. Mina, Ibrahim Muhsen, Ethan Burns, Humaira Sarfraz, Sai Ravi Pingali, Jiaqiong Xu, Shahrukh K. Hashmi
Format: Article
Language:English
Published: Galenos Publishing House 2021-08-01
Series:Turkish Journal of Hematology
Subjects:
multiple myeloma
proteasome inhibitors
peripheral neuropathy
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-28913

Internet

https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-28913

Similar Items